A bond between Lausanne and Eindhoven

GTX medical is based on two of the most productive sites for science and technology in Europe. In Lausanne, we are associated with the world-class research conducted at the Technical and Life Science Faculties of EPFL.

In the Netherlands we are based on the High Tech Campus Eindhoven, which is one of the Europe’s most attractive hubs for high-tech developments. Combining the expertise of both sites results in a unique and dynamic fertilization that forms the basis for building world class neuromodulation devices.

Our Leadership Team

CEO

Sjaak is CEO and an experienced MedTech executive with ample experience in fund-raising and creating and growing a MedTech company for complex Class III medical devices. Over 25 years of experience in R&D project management, product management, creating and managing alliances, and early stage venturing, mainly for MedTech and Healthcare products. He worked for Phillips Medical, Phillips Healthcare and Medtronic. He is the founding CEO of Sapiens Steering Brain Stimulation, a company for which he has raised 48 m€ to grow it from 3 to 64 employees in less than 4 years, when the company was sold to Medtronic. Sjaak joined GTX in February 2015.

CSO

Grégoire Courtine was trained in Mathematics, Physics, and Neurosciences. He received his PhD degree in Experimental Medicine in France in 2003. After obtaining the Chancellor Award during his post-doctoral training at the University of California Los Angeles (UCLA), where he was also associate for the Christopher and Dana Reeve Foundation, he established his own laboratory at the University of Zurich in 2008. He received the Schellenberg Prize for his work in paraplegia and fellowships from the European Research Council in 2009 and 2016 to support his frontier research in neuroscience. In 2012, he became Associate Professor at the International Paraplegic Foundation (IRP) chair in Spinal Cord Repair in the Center for Neuroprosthetics at the Swiss Federal Institute of Technology, Lausanne (EPFL). Over the past 15 years, Grégoire and his team have implemented a multidisciplinary research program with the aim to develop new treatment paradigms for spinal cord injury. The results of this research were recognized in various high-profile publications such as Science and Nature journals, and discussed extensively in national and international media.

CTO

Bert is CTO and an experienced executive with over 25 years of experience in Research and Development. He has been leading cross-functional teams in the development of high-risk (Class III) medical devices. He worked for Philips Research, Sapiens Steering Brain Stimulation and Medtronic. Bert is a recognized expert in electronics, and he has a vast experience in requirements management, system design and architecture, translation into sub-system and system interface specifications. He has a proven track-record in successful managing internal and external partners. Bert is an empathic people manager and result driven team player with good stakeholder management, communication, coaching and teaching skills. Bert joined GTX after founding of the company.

COO

Vincent is COO and has spun off the project from EPFL after a two year incubation period during which early business development actions were undertaken, including: initial IP preparation and filing, pilot clinical study preparation, research contracts with academic partners. His entrepreneurial activity was awarded of several prizes and grants: Innogrant (2013), Venture Kick I & II (2013, 2014), Venture – Best Business Idea (2014), Venture Leaders (2014), Hello Tomorrow Challenge – Grand Prize (2014), Perl – prix coup de Coeur (2014), Innovation Prize (2014), Wellcome Trust feasibility award (2015). Vincent is an engineer with a PhD in Neurosciences (EPFL), his scientific work focused on the impact of electrical stimulation on mechanisms of neural circuits re-organization.

CFO

Marko is CFO and has over 20 years experience in managing and analysing a variety of business and their processes. After he has worked for almost 10 years in public accounting with Arthur Andersen, Marko switched to the other side of the table and worked for more than 10 years in various (financial) management roles within ERICO and AudioNova. He also had (financial) advisory roles within several medium to small-sized companies. Marko joined
G-Therapeutics in July 2017.

VP Clinical Regulatory

Hendrik has over 20 years of experience in implementing and conducting clinical studies in Europe and the US. He has been successfully leading the clinical & regulatory strategies for high-risk (Class III) medical devices, from conception to FDA market approval. Hendrik owns a PhD in Biomedical Engineering and most recently, he was Vice-President Clinical & Regulatory Affairs at Endosense (Geneva, Switzerland) until the company’s acquisition by St-Jude Medical in 2013. Hendrik and joined G-Therapeutics in November 2015.

Our Supervisory Board

Chairman

Dr Öhrström was responsible for the incorporation of ProFibrix Inc and ProFibrix BV, which included a full private fundraising and development through Phase III of a product/device combination (Fibrocaps/Raplixa) as well as securing product approval in US and EU. He has also held executive positions including Senior Vice President at ZymoGenetics, Seattle, WA, USA, and CEO at ProFibrix BV, The Netherlands, and is currently Chairman of the Board & President at Biomup SA, Lyon, France, and a board director at Blaze Bioscience inc, Seattle, WA, USA. Dr Öhrström began his career as a clinician and held a number of clinical positions at Novo Nordisk before moving into business orientated positions. Dr Öhrström is a Danish citizen and resident in the Netherlands.

Boardmember

Patrick Van Beneden joined Gimv in 1985 and has built a successful track record in life sciences, both in early and late stage investments and exits (Devgen, CropDesign, Plexxikon, Endosense,…). He is currently representing Gimv on the boards of JenaValve, Complix, AgroSavfe, G-Therapeutics and FlandersBio and holds an observer seat at EndoStim. Former board seats include Innogenetics, Crucell, Hypnion (acquired by Eli Lilly), CropDesign (acquired by BASF), Astex and Ablynx. Patrick has a degree in financial sciences from Vlekho in Brussels.

Board Member

Fred Colen is a seasoned business executive with years of experience leading small, medium and large medical device businesses throughout the world. Fred has been a successful business innovator in commercialization of new medical technology products. He was President/CEO of BeneChill, a brain cooling company and President of the Boston Scientific Cardiac Rhythm Management Group. Furthermore he has served as Boston Scientifics’ Chief Technology Officer for eight years. Born and raised in the Netherlands, he obtained a Masters Degree in Electrical Engineering with specialization in BioMedical Technology from the RWTH Aachen, Germany. He has served on several Boards: Mölnlycke Healthcare, Middle Peak Medical and College of Science & Engineering at the University of Minnesota.

Board Member

Regina is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Endostim, GTX,Themis, Rigontec, Middle Peak Medical, Ayoxxa, and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GlaxoSmithKline’s Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.

Board Member

Jan Keltjens currently holds a number of non-executive Board roles, including Chairman of the Boards of JenaValve Technologies and NightBalance He is also associated with the venture capital funds Syncona (London) and INKEF (Amsterdam). He most recently served as chief executive officer of Sapiens Steering Brain Stimulation (acquired by Medtronic in August 2014). Before that he previously was the chairman and chief executive officer of Endosense SA (acquired by St Jude Medical in August 2013), executive chairman of Surpass Medical ltd. (acquired by Stryker Corporation late 2012), as well as president and chief executive officer of AngioDynamics Inc. (ANGO, 2009 – 2011) and CryoCath Technologies Inc. (TSX; CYT, 2007- until its acquisition by Medtronic in 2009). From 2000 to 2007, he served as Worldwide General Manager of Cordis Neurovascular, a Johnson & Johnson company. He joined Cordis in 1995 as Vice President and Managing Director responsible for international manufacturing and distribution operations, as well as research and development. He was promoted to Vice President of European Marketing for all Cordis divisions in 1998 and Vice President of Worldwide Strategic Marketing for Cordis Cardiology, based in Miami, in 1999. Before joining Cordis, Mr. Keltjens led research and development departments at Unilever and was Managing Director of a group of small high tech companies.

Board Member

John de Koning, Ph.D. is a partner at LSP (Life Sciences Partners), one of Europe’s leading investors in the healthcare sector. In addition to G-Therapeutics, John currently serves on the boards of argenx, Merus and eTheRNA. He also served on the boards of several other companies, such as BMEYE (acquired by Edwards Lifesciences) and Prosensa (acquired by BioMarin). Prior to joining LSP in 2006, John was the Managing Director of Semaia Pharmaceuticals (acquired by Hybrigenics). Previously, he was a senior researcher within several prestigious medical research labs and worked with, among others, Prof. Hans Clevers, Prof. Bob Löwenberg and Prof. Allan Balmain. John has a Master’s degree in Medical Biology from the University of Utrecht and a Ph.D. in Oncology from the Erasmus University Rotterdam, both in the Netherlands. After obtaining his Ph.D., he received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics.

CSO

Grégoire Courtine was trained in Mathematics, Physics, and Neurosciences. He received his PhD degree in Experimental Medicine in France in 2003. After obtaining the Chancellor Award during his post-doctoral training at the University of California Los Angeles (UCLA), where he was also associate for the Christopher and Dana Reeve Foundation, he established his own laboratory at the University of Zurich in 2008. He received the Schellenberg Prize for his work in paraplegia and fellowships from the European Research Council in 2009 and 2016 to support his frontier research in neuroscience. In 2012, he became Associate Professor at the International Paraplegic Foundation (IRP) chair in Spinal Cord Repair in the Center for Neuroprosthetics at the Swiss Federal Institute of Technology, Lausanne (EPFL). Over the past 15 years, Grégoire and his team have implemented a multidisciplinary research program with the aim to develop new treatment paradigms for spinal cord injury. The results of this research were recognized in various high-profile publications such as Science and Nature journals, and discussed extensively in national and international media.

TBD